Table 3.
Characteristics, Tumor Type, and Outcome for Patients with Second Malignancies after Treatment for ESFT
| Ewing Sarcoma Family of Tumors | Second Malignancy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt. No. | Sex | Race | Age at Dx (yrs) | Sites of Disease | Treatment | Age at Diagnosis (yrs) | Time from Dx of ESFT (yrs) | Type | Cytogenetics | Outcome, yrs from second malignancy | |
| Chemotherapy | Radiation Dose (Site) | ||||||||||
| 1 | M | W | 14.5 | Rib | ES79 | 35 Gy (spine C7-T5) | 34.1 | 19.6 | ALL | NA | D, 1.3 |
| 2 | F | W | 12.6 | llium | ES79 | 54 Gy (pelvis) | 22.1 | 9.4 | Squamous cell carcinoma of cervix | – | A, 5.9 |
| 3 | F | H | 14.0 | Leg, LN, Lung | EWI-92-HD Paclitaxel after relapse | 66.4 Gy (inguinal and iliac LN); 16.5 Gy (WLI) | 21.4 | 7.4 | Extraosseous pelvic osteosarcoma | – | D, 4.8 |
| 4 | F | W | 7.3 | Neck | EWI-92-HD | 36 Gy (neck) | 11.3 | 4.0 | MDS (RA) | 46,XX,der(6)t(1;6)(q12;p22.2) | D, 1.3 |
| 5 | M | W | 13.7 | Radius | EWI-92 | 68.4 Gy (radius) | 22.0 | 8.3 | Osteosarcoma of radius | – | A, 4.9 |
| 6 | M | W | 14.2 | Hand | EWI-92 | 39.6 Gy (hand) | 16.9 | 2.6 | MDS (RAEB) | 46,XY,del(7)(q22) | D, 0.5 |
| 7 | F | H | 7.9 | Sacrum | POG 9354, Reg. B | 55.8 Gy (sacrum) | 15.6 | 7.7 | Thyroid papillary carcinoma | – | A, 3.5 |
| 8 | F | W | 13.8 | Foot | POG 9354, Reg. A | None | 15.6 | 1.8 | MDS (RAEB) then AML | 46,XX,del(7)(q22q34) | D, 0.4 |
| 9 | M | H | 16.2 | L3 Vertebra | POG 9354, Reg. B | 55.8 Gy (lumbar spine) | 17.6 | 1.4 | ALL | 46,XY,inv(11)(q21q23.3)der(17)t[inv(11);17](q13;q25) | D, 0.6 |
| 10 | M | W | 2.6 | Pelvis | SJBCM | None | 4.4 | 1.8 | AML (M4) | 46,XY,inv(16)(p13.1q22) | D, 0.9 |
| 11 | F | W | 22.0 | Chest wall | SJBCM | 55.6 Gy (chest wall) | 24.6 | 2.7 | MDS (RAEB) then AML | 45,XX,-7 | D, 0.2 |
| 12 | M | W | 13.7 | Hand | SJBCM | None | 16.2 | 2.5 | AML | 47, XY, inv(16)(p13.1q22), +22 | A, 1.4 |
Abbreviations: Dx, diagnosis; M, male; F, female; W, White; H, Hispanic; SJBCM, St. Jude Best Clinical Management; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; A, alive; D, dead; WLI, whole lung irradiation; NA, not available; LN, lymph node; RAEB, refractory anemia with excessive blasts; RA, refractory anemia.